A summary of the research appears in the journal Developmental Cell on Oct. 27. The mystery of the gene, TEM5, began in 2000 with research conducted by Brad St. Croix, Ph.D., working in the laboratory of Bert Vogelstein, M.D., a Howard Hughes Medical Institute investigator and the Clayton Professor of Oncology, and Kenneth Kinzler, Ph.D., professor of oncology at the Johns Hopkins University School of Medicine…
In the AlphaMed Press journal Stem Cells, Shah’s team shows how the toxin-secreting stem cells can be used to eradicate cancer cells remaining in mouse brains after their main tumor has been removed. The stem cells are placed at the site encapsulated in a biodegradable gel. …
Breast cancer is the most common non-skin cancer in women worldwide, and the second leading cause of women’s cancer mortality in the United States. A common treatment strategy after diagnosis is to shrink breast cancer tumors larger than 3 centimeters with a 6- to 8-month course of NAC prior to surgery. Clinical studies have shown that patients who respond to NAC have longer disease-free survival rates, but only 20 to 30 percent of patients who receive NAC fit this profile…
Survival outcomes remain poor for lung cancer patients in large part because of lung cancer’s resistance to conventional therapies. …
This gap in communication can happen when patients believe that their doctors are indifferent or negative toward their use of these supplements. As a result, patients may find information about dietary supplements from unreliable sources, exposing themselves to unneeded risks. Since information on these dietary supplements is limited, researchers from the University of Texas Medical Branch describe a practical patient-centered approach to managing dietary supplement use in cancer care in a review article. Improving the communication between patient and doctor in this area is critical. …
The Duke researchers shared their findings at the Palliative Care in Oncology Symposium sponsored by the American Society of Clinical Oncology. In the new treatment model, medical oncologists and palliative care physicians partnered in a “co-rounding” format to deliver cancer care for patients admitted to Duke University Hospital’s solid tumor unit. The Duke model fostered collaboration and communication between the specialists, who met several times a day to discuss patient care…
Delivering cancer drugs directly to tumors is difficult. Scientists are working on new approaches to overcome the natural limitations of drugs, including loading them into nanoparticles. “The drug is packaged into a lipid ball significantly smaller than the width of a hair to make it soluble in the blood stream and prevent negative side effects. The drug-containing nanoparticle ball then travels in the bloodstream to the tumor, where it accumulates and the drug is released in the tumor to kill the cancer cells,” said Gavin Robertson, professor of pharmacology, pathology, dermatology, and surgery and director of the Penn State Hershey Melanoma Center. …
“Exposure to artificial light leads to a significantly higher risk for developing breast cancer,” said Chunla He, a biostatistics graduate student in the UGA College of Public Health. “To decrease the use of artificial light, people should avoid working at night and implement earlier bed times.” Her research, published in the International Archives of Occupational and Environmental Health, examined key studies that included risk factors for developing breast cancer. …
It’s a familiar scenario, played out hundreds of times in the movies. But the dramatic scene is reenacted in real life every time a cell divides. In order for division to occur, our genetic material must be faithfully replicated by a highly complicated machine, whose parts are tiny enough to navigate among the strands of the double helix. The problem is that our DNA is constantly in use, with other molecular machines continually plucking at its strands to gain access to critical genes. …
The gene ErbB2, commonly called HER2, is highly expressed in about 25 percent of breast cancers. Scientists have now found the protein Erbin, thought to be an anti-tumor factor, also is highly expressed in these cancers and essential to ErbB2’s support of breast cancer. When scientists interfere with the interaction between the two in mice, it inhibits tumor development and the usual spread to the lungs, according to an international team reporting in the journal PNAS. The team documented the overexpression of both in 171 cases of mostly aggressive human breast cancer as well. …